On April 26, 2022 TG Therapeutics, Inc. (NASDAQ: TGTX), reported that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a fireside chat during the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference, taking place on Thursday, April 28, 2022, at 12:30 PM ET (Press release, TG Therapeutics, APR 26, 2022, View Source [SID1234612949]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of this fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at View Source A replay of the webcast will be available on TG’s website following the event.

On April 26, 2022 Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, reported plans to report first quarter financial results on Tuesday, May 10, 2022, before market open (Press release, Rubius Therapeutics, APR 26, 2022, View Source [SID1234612967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will not be hosting a teleconference in conjunction with its financial results press release.

On April 26, 2022 PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company reported that the Company will host a business update conference call on Thursday, May 12, 2022, at 4:30 PM EDT (Press release, PAVmed, APR 26, 2022, View Source [SID1234612984]). During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, PAVmed’s Chief Financial Officer, will discuss the Company’s first quarter 2022 financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, U.S.-based listeners should dial 800-458-4121 and international listeners should dial 856-344-9290. All listeners should provide the operator with the conference call name "PAVmed, Inc. Business Update Conference Call" to join. Individuals interested in listening to the live conference call via the webcast may do so by visiting the investor relations section of the Company’s website at www.pavmed.com.

Following the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing 844-512-2921 from within the U.S. or 412-317-6671 from outside the U.S. To access the replay, all listeners should provide the following pin number: 7771455. The webcast will be available for replay on the investor relations section of the Company’s website at www.pavmed.com.

On April 26, 2022 GT Medical Technologies, Inc. reported that new data on the company’s innovative GammaTile Therapy for patients with operable brain tumors will be presented via an oral, live presentation at the 2022 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Philadelphia, PA (Press release, GT Medical Technologies, APR 26, 2022, View Source [SID1234613000]). The abstract will provide the first report of clinical outcomes for recurrent glioblastoma patients treated with FDA-cleared GammaTile Therapy. Impressive clinical outcomes were reported, with a Median Local Control of 81% at 12 months and Median Overall Survival reaching 37 months in MGMT methylated patients. The safety profile was comparable to patients undergoing repeat surgery without GammaTile treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GammaTile Therapy is a bioresorbable 3D-collagen tile embedded with Cesium-131 sources that is implanted in the last five minutes of brain tumor removal surgery. The sustained, controlled, and therapeutic dose of radiation immediately begins targeting remaining tumor cells, sparing healthy tissue. "There is no established standard of care today for patients with recurrent glioblastoma. This abstract, along with other studies and clinical publications, supports that GammaTile Therapy should be considered for all patients with operable recurrent glioblastomas," says Matthew Likens, President and CEO of GT Medical Technologies. "Patients receiving GammaTile Therapy have the benefit of prolonged survival without sacrificing quality of life. Our company purpose is to improve the lives of patients with brain tumors, and Dr. Chen’s early clinical experience at University of Minnesota advances this purpose."

The abstract will provide a report of clinical outcomes for recurrent GBM patients treated with FDA-cleared GammaTile.

The abstract, titled GammaTile Brachytherapy in the Treatment of Recurrent Glioblastomas, earned lead author Clark C. Chen, MD, PhD, M Health Fairview neurosurgeon and the head of the University of Minnesota Medical School Department of Neurosurgery, the prestigious Brainlab Neurosurgery Award. This award is presented at both the annual meetings of AANS and the Congress of Neurological Surgeons (CNS) and is given to a neurosurgeon with a high-scoring abstract relating to central nervous system tumors.

"The treatment of recurrent glioblastoma remains a major challenge in our field, without consensus for a standard of care. Our published results suggest clinical benefit from GammaTile treatment and warrant consideration in this setting, especially given the highly favorable safety profile," said Dr. Chen. "Recapitulation of our results in a larger, multi-institution cohort has the potential to redefine the standard of care for recurrent glioblastoma patients."

The abstract will be presented on Monday, May 2nd at 4:16 PM in the Tumor Abstract Session in Philadelphia. This will be the first in-person AANS meeting since 2019. Read the abstract here.

On April 26, 2022 Abbott (NYSE: ABT) reported that received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation (TRC) to purchase up to 1,000,000 Abbott common shares, representing approximately 0.06% of the company’s outstanding shares (Press release, Abbott, APR 26, 2022, View Source [SID1234612952]). TRC’s offer price of $112.38 per share in cash is approximately 4.5% lower than the $117.69 closing price of Abbott common shares on April 14, 2022, the last closing price prior to commencement of the offer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abbott does not recommend or endorse TRC’s unsolicited below-market mini-tender offer and recommends that shareholders not tender their shares because the offer is at a price significantly below the current market price of Abbott common shares. Abbott is not affiliated or associated in any way with TRC, its mini-tender offer or the mini-tender offer documentation.

Abbott urges shareholders to obtain current market quotations for their shares, to consult with their broker or financial advisor, and to exercise caution with respect to TRC’s mini-tender offer. Abbott recommends that shareholders who have not responded to TRC’s offer take no action. Abbott also recommends that shareholders who have already tendered their shares withdraw those shares in accordance with TRC’s offering documents prior to the expiration of the offer. The offer is currently scheduled to expire at 12:01 a.m. New York City time on Tuesday, May 17, 2022, unless the offer is extended or earlier terminated.

TRC has made similar below-market mini-tender offers for other companies’ shares. Mini-tender offers are devised to seek less than 5% of a company’s stock, thereby avoiding many filing, disclosure and procedural requirements of the U.S. Securities and Exchange Commission (SEC).

The SEC has cautioned investors that some bidders making mini-tender offers at below-market prices are "hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price." The SEC’s guidance to investors on mini-tender offers is available at View Source

Abbott encourages brokers and dealers, as well as other market participants, to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosure at View Source

Abbott requests that a copy of this press release be included with all distributions of materials relating to TRC’s mini-tender offer related to Abbott common shares.